American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Polatuzumab Vedotin + Obinutuzumab + Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma

ASH 2019 – Wrap-up, ASH 2019 – CLL

Primary analysis results of a phase 1b/2 trial showed obinutuzumab + polatuzumab vedotin + lenalidomide was associated with high complete response rates and a favorable safety profile in heavily pretreated and refractory patients with follicular lymphoma. Read More ›

Ibrutinib + Rituximab versus FCR in Younger Patients with CLL: Extended Follow-Up of E1912 Trial

ASH 2019 – Post Wrap-Up, ASH 2019 – CLL

Extended follow-up of the E1912 trial showed a significant advantage for patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib + rituximab compared with those treated with fludarabine, cyclophosphamide, and rituximab (FCR). Read More ›

Bruton Tyrosine Kinase Inhibitor Zanubrutinib in Patients with CLL and SLL

ASH 2019 – CLL

Zanubrutinib is an investigational, next-generation Bruton tyrosine kinase inhibitor. It has been tested in previously untreated patients with del(17p) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who are enrolled in the SEQUOIA trial. Read More ›

CAR T-Cell Therapy: A New Treatment for Myeloma?

ASH 2019 – Multiple Myeloma: Wrap-Up

CAR T-cell therapy – a type of cancer treatment that uses specially altered T-cells from the human body to attack cancer cells – could soon be used to fight multiple myeloma. CAR T-cell therapy has shown huge promise in other types of cancer but would be a new treatment for patients with this type of cancer. Read More ›

Venetoclax plus Ibrutinib in Mantle-Cell Lymphoma

ASH 2019 – CLL

An updated analysis of combined or pooled data from studies of ibrutinib. For the first time, a comparison of outcomes with ibrutinib versus patients’ prior treatment regimens for mantle-cell lymphoma is shared. Read More ›

Zanubrutinib Shows High Overall Response Rate and Durable Responses in CLL and SLL

ASH 2019 – CLL

Zanubrutinib is a next-generation Bruton tyrosine kinase inhibitor that has been shown to be potent and selective. Preliminary data suggest durable clinical responses in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Read More ›

This 3-Drug Combo Improves Survival, But Does it Lower Quality of Life? Investigators Say No

ASH 2019 – Multiple Myeloma: Wrap-Up

Exciting new research shows that adding daratumumab to a common multiple myeloma treatment slowed down cancer progression in patients who had relapsed or did not respond to other treatments. Read More ›

Zanubrutinib in Patients with Treatment-Naïve CLL/SLL with del(17p): Initial Results from Arm C of the SEQUOIA (BGB-3111-304) Trial

ASH 2019 – Wrap-up, ASH 2019 – CLL

Preliminary results of the SEQUOIA trial suggested that zanubrutinib was active and generally well tolerated in treatment-naïve patients with del(17p) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Read More ›

Ixazomib, Rituximab, and Dexamethasone in Patients with Relapsed or Progressive Waldenström Macroglobulinemia

ASH 2019 – Post Wrap-Up, ASH 2019 – CLL

The ongoing phase 1/2 HOVON 124/Ecwm-R2 trial showed the combination of ixazomib citrate, rituximab, and dexamethasone to be feasible, with promising efficacy and manageable toxicity in patients with relapsed or progressive Waldenström macroglobulinemia. Read More ›

Lisocabtagene Maraleucel, a CD19-Directed CAR T-Cell Therapy

ASH 2019 – CLL

Chimeric antigen receptor (CAR) T-cells represent a novel and exciting strategy for patients with blood cancers. This study evaluated lisocabtagene maraleucel, an investigational CAR T-cell product, for patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Read More ›

American Society of Hematology (ASH)

Page 16 of 44